Alzamend Neuro, Inc. (ALZN)Healthcare | Biotechnology | Atlanta, United States | NasdaqCM
1.16 USD
-0.02
(-1.695%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.17 +0.01 (0.862%) ⇧ (July 13, 2026, 4:38 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:13 a.m. EDT
The short-term outlook remains cautiously bearish due to a persistent downtrend against the 200-day average and a statistical forecast showing no directional edge, despite a minor recent bounce. However, the long-term investment case is effectively zero; the business has suffered a catastrophic multi-year decline with four consecutive years of negative annual returns, erasing nearly 99.96% of its value over the last four years. This trajectory indicates severe structural deterioration where the market has repeatedly rejected the company's performance. Furthermore, there is no dividend income to offset these massive capital losses, making the security unsuitable for any standard investment strategy. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.059809 |
| MSTL | 0.065263 |
| AutoARIMA | 0.074878 |
| AutoTheta | 0.309764 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 2.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.742 |
| Excess Kurtosis | 0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,413,499 |
| Forward P/E | -0.45 |
| Beta | 0.14 |
| Website | https://www.alzamend.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.62658226 |
| Address1 | 3,480 Peachtree Road NE |
| Address2 | Second Floor, Suite 103 |
| All Time High | 45,292.5 |
| All Time Low | 0.84 |
| Ask | 1.47 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 555,090 |
| Average Daily Volume3 Month | 153,339 |
| Average Volume | 153,339 |
| Average Volume10Days | 555,090 |
| Beta | 0.142 |
| Bid | 0.8424 |
| Bid Size | 2 |
| Book Value | 0.574 |
| City | Atlanta |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.16 |
| Current Ratio | 1.992 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.2033 |
| Day Low | 1.1201 |
| Display Name | Alzamend Neuro |
| Earnings Timestamp End | 1,754,164,800 |
| Earnings Timestamp Start | 1,753,732,800 |
| Ebitda | -6,939,160 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.245 |
| Enterprise Value | 1,700,360 |
| Eps Current Year | -2.58 |
| Eps Forward | -2.6 |
| Eps Trailing Twelve Months | -3.61 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.1491 |
| Fifty Day Average Change | 0.010900021 |
| Fifty Day Average Change Percent | 0.009485703 |
| Fifty Two Week Change Percent | -62.658226 |
| Fifty Two Week High | 3.6 |
| Fifty Two Week High Change | -2.44 |
| Fifty Two Week High Change Percent | -0.6777778 |
| Fifty Two Week Low | 0.84 |
| Fifty Two Week Low Change | 0.32 |
| Fifty Two Week Low Change Percent | 0.3809524 |
| Fifty Two Week Range | 0.84 - 3.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,763,800,000 |
| Float Shares | 3,792,870 |
| Forward Eps | -2.6 |
| Forward P E | -0.44615385 |
| Free Cashflow | -3,615,899 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0053 |
| Held Percent Institutions | 0.030350002 |
| Implied Shares Outstanding | 3,804,741 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,745,971,200 |
| Last Split Date | 1,747,008,000 |
| Last Split Factor | 1:9 |
| Long Business Summary | Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. |
| Long Name | Alzamend Neuro, Inc. |
| Market | us_market |
| Market Cap | 4,413,499 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_367712111 |
| Most Recent Quarter | 1,769,817,600 |
| Net Income To Common | -7,544,730 |
| Next Fiscal Year End | 1,777,507,200 |
| Non Diluted Market Cap | 4,489,594 |
| Number Of Analyst Opinions | 1 |
| Open | 1.1499 |
| Operating Cashflow | -5,959,224 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 844 722 6333 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.8620682 |
| Post Market Price | 1.17 |
| Post Market Time | 1,783,975,080 |
| Previous Close | 1.18 |
| Price Eps Current Year | -0.4496124 |
| Price Hint | 4 |
| Price To Book | 2.020906 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.461 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -1.69491 |
| Regular Market Day High | 1.2033 |
| Regular Market Day Low | 1.1201 |
| Regular Market Day Range | 1.1201 - 1.2033 |
| Regular Market Open | 1.1499 |
| Regular Market Previous Close | 1.18 |
| Regular Market Price | 1.16 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 46,364 |
| Return On Assets | -1.07011 |
| Return On Equity | -2.49965 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,804,741 |
| Shares Percent Shares Out | 0.0414 |
| Shares Short | 157,517 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 149,007 |
| Short Name | Alzamend Neuro, Inc. |
| Short Percent Of Float | 0.0416 |
| Short Ratio | 0.84 |
| Source Interval | 15 |
| State | GA |
| Symbol | ALZN |
| Target High Price | 25.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 25.0 |
| Total Cash | 2,713,139 |
| Total Cash Per Share | 0.713 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.61 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.790155 |
| Two Hundred Day Average Change | -0.6301551 |
| Two Hundred Day Average Change Percent | -0.35201144 |
| Type Disp | Equity |
| Volume | 46,364 |
| Website | https://www.alzamend.com |
| Zip | 30,326 |